Who Generates More Revenue? Sarepta Therapeutics, Inc. or Ionis Pharmaceuticals, Inc.

Sarepta's revenue surge challenges Ionis in biotech race.

__timestampIonis Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.
Wednesday, January 1, 20142141610009757000
Thursday, January 1, 20152837030001253000
Friday, January 1, 20163466200005421000
Sunday, January 1, 2017507666000154584000
Monday, January 1, 2018599674000301034000
Tuesday, January 1, 20191123000000380833000
Wednesday, January 1, 2020729000000540099000
Friday, January 1, 2021810000000701887000
Saturday, January 1, 2022587000000933013000
Sunday, January 1, 20237876470001243336000
Monday, January 1, 2024705138000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Battle: Sarepta vs. Ionis

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Ionis Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have been at the forefront of this race. From 2014 to 2023, Ionis consistently outperformed Sarepta in revenue, peaking in 2019 with a staggering 1.12 billion dollars. However, Sarepta has shown remarkable growth, especially in recent years. By 2023, Sarepta's revenue surged to 1.24 billion dollars, surpassing Ionis for the first time. This represents a dramatic increase of over 12,600% from its 2014 revenue. Ionis, on the other hand, experienced fluctuations, with a notable dip in 2022. The data highlights a shifting dynamic in the biotech industry, where innovation and strategic investments are crucial. As Sarepta continues its upward trajectory, the question remains: Can Ionis reclaim its lead?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025